Idorsia (LTS:0RQE) Equity-to-Asset

: -1.27 (As of Sep. 2023)

View and export this data going back to 2017. Start your Free Trial

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Idorsia's Total Stockholders Equity for the quarter that ended in Sep. 2023 was CHF-831.0 Mil. Idorsia's Total Assets for the quarter that ended in Sep. 2023 was CHF653.1 Mil. Therefore, Idorsia's Equity to Asset Ratio for the quarter that ended in Sep. 2023 was -1.27.

The historical rank and industry rank for Idorsia's Equity-to-Asset or its related term are showing as below:

LTS:0RQE' s Equity-to-Asset Range Over the Past 10 Years
Min: -1.97 Med: 0.3 Max: 0.63
Current: -1.27

During the past 7 years, the highest Equity to Asset Ratio of Idorsia was 0.63. The lowest was -1.97. And the median was 0.30.

LTS:0RQE's Equity-to-Asset is ranked worse than
92.39% of 1564 companies
in the Biotechnology industry
Industry Median: 0.66 vs LTS:0RQE: -1.27

Idorsia Equity-to-Asset Historical Data

The historical data trend for Idorsia's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Idorsia Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Equity-to-Asset

0.47

0.17

0.41

0.07

-0.73

Idorsia Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Equity-to-Asset																-0.53	-0.73	-1.23	-1.97	-1.27

Competitive Comparison

For the Biotechnology subindustry, Idorsia's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Idorsia Equity-to-Asset Distribution

For the Biotechnology industry and Healthcare sector, Idorsia's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Idorsia's Equity-to-Asset falls into.

Idorsia Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Idorsia's Equity to Asset Ratio for the fiscal year that ended in Dec. 2022 is calculated as

Equity to Asset (A: Dec. 2022 )	=	Total Stockholders Equity	/	Total Assets
	=	-660.958	/	904.18
	=	-0.73

Idorsia's Equity to Asset Ratio for the quarter that ended in Sep. 2023 is calculated as

Equity to Asset (Q: Sep. 2023 )	=	Total Stockholders Equity	/	Total Assets
	=	-831.001	/	653.12
	=	-1.27

Idorsia (LTS:0RQE) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.

Idorsia Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Idorsia's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Idorsia (LTS:0RQE) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Idorsia Ltd (LTS:0RQE) » Definitions » Equity-to-Asset

Comparable Companies

Traded in Other Exchanges

IDRSF:USA IDIAz:UK IDIA:Switzerland

Address

Hegenheimermattweg 91, Allschwil, CHE, 4123

Website

https://www.idorsia.com

Idorsia Ltd is a biopharmaceutical company engaged in discovering, developing, and commercializing of medicines for unmet medical needs. It is a biotech hub of Europe specialized in the discovery and development of small molecules, to provide innovative therapeutic options. The company focuses on multiple therapeutic areas which include the central nervous system, cardiovascular disorders, immunological disorders, and orphan diseases. Idorsia's development compounds target a number of different diseases such as Resistant Hypertension, lupus, insomnia, Cerebral vasospasm, and Fabry disease. Geographically, it derives revenue from Switzerland.

Idorsia (LTS:0RQE) Headlines

No Headlines